GLOW 70mg Peptide Blend

Description

GLOW 70mg peptide blend, with each component documented

Purity Collective supplies the GLOW 70mg Peptide Blend in a lyophilized vial for qualified laboratory research. The catalog formulation lists BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg. This page places the formulation, SKU and available analytical records together so a purchasing team can compare the listed material with its procurement request before checkout.

For a multi-component blend, the evidence boundary matters. The 70mg catalog total is the sum of the three listed specifications. The attached UPLC/MS report presents a separate quantity and purity result for each submitted component sample; it does not state one blend-wide purity percentage. The numerical results below remain tied to the report and lot that produced them.

GLOW 70mg composition and catalog details

• Catalog total: 70mg across three listed components
• Format: Lyophilized vial
• SKU: PC-GLOW-70MG
• UPLC/MS lot: PCCL-6203251
• Endotoxin document lot: PCCL-6203251-E

Review the GLOW analytical documents

Open the complete GLOW 70mg component UPLC/MS report and the separate GLOW 70mg endotoxin document. Purity Collective’s guide to reading a peptide COA explains how to compare identity, lot, method, specification, dates and results without extending a sample result beyond its record. For a blend-level source and component-boundary overview, read the GLOW peptide blend research records and component review guide.

The six-page UPLC/MS report identifies lot PCCL-6203251 and contains a dedicated panel for each listed component. The table above transcribes its component-specific quantity and purity results. Every panel prints a purity specification of at least 98%. The report records March 29, 2026 as the analysis date and March 31, 2026 as the received date, placing the stated analysis two days before receipt.

The separate endotoxin document identifies the three-component GLOW formulation under related lot PCCL-6203251-E and records a result below 0.05 EU/mL. It prints April 3, 2026 as the analysis date and April 8, 2026 as the received date, placing the stated analysis five days before receipt. The document does not print an endotoxin acceptance specification, so this page does not label the result a pass or infer sterility, safety, suitability or performance.

Compare GLOW, KLOW and the standalone components

The listed difference between this GLOW 70mg formulation and the KLOW 80mg Peptide Blend is KPV 10mg: KLOW lists the same BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg specifications plus KPV 10mg. Buyers should still review each product’s own lot-specific records rather than treating the two blends as analytically interchangeable.

Purity Collective also lists BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg as standalone catalog products. Those pages can help a buyer compare names, quantities and formats, but their attached reports belong to different products and lots. Standalone evidence must not be used to characterize this GLOW blend.

Before you order GLOW 70mg

• Confirm that the three-component formulation and SKU PC-GLOW-70MG match the procurement request.
• Review all six UPLC/MS pages and the separate endotoxin document, including their lot identifiers and dates.
• Keep each quantity and purity measurement tied to its named component and submitted sample.
• Record both analysis-before-receipt sequences and the absence of a printed endotoxin acceptance specification.
• Apply your laboratory’s own supplier-qualification, acceptance, storage and handling procedures.

GLOW 70mg peptide blend FAQs

What is in the GLOW 70mg peptide blend?

The catalog formulation lists BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg, for a listed total of 70mg in one lyophilized vial.

Does GLOW 70mg have one blend-wide purity result?

No single blend-wide purity percentage is stated in the attached report. It presents separate purity results for BPC-157, TB-500 and GHK-Cu. Each result should stay associated with its component panel and submitted lot.

Which GLOW documents and limitations should I review?

The page links to a six-page component UPLC/MS report and a separate endotoxin document. The first lists analysis two days before receipt; the second lists analysis five days before receipt and contains no printed endotoxin acceptance specification.

How is GLOW 70mg different from KLOW 80mg?

Both catalog formulations list BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg. KLOW also lists KPV 10mg, bringing its catalog total to 80mg. Each blend has its own lot-specific documents and must be evaluated separately.

Is the GLOW peptide blend intended for human use?

No. GLOW 70mg is supplied only for qualified laboratory research and is not for human or veterinary administration. Purity Collective does not provide clinical, therapeutic, dosing or administration guidance.

Research-use notice

For qualified laboratory research only. Not for human or veterinary administration. This listing is not presented as a medicine or treatment.